Table 1.
Evaluable patient demographics and diagnoses.
| Total Sequenced | n = 55 (%) |
|---|---|
| Cases | 47 (85.5) |
| Controls | 8 (14.5) |
| Age | |
| Median age | 8 y |
| Age range | 2 mo to 21 y |
| Sex | |
| Male | 28 (50.9) |
| Female | 27 (49.1) |
| Metastatic | |
| M0 | 40 (85.1) |
| M+ | 7 (14.9) |
| Tumor location | |
| Posterior fossa | 21 (44.7) |
| Sellar or suprasellar | 7 (14.9) |
| Optic pathway | 5 (10.6) |
| Lateral ventricle | 3 (6.4) |
| Brainstem/ midline | 3 (6.4) |
| Frontal lobe | 2 (4.3) |
| Parietal lobe | 2 (4.3) |
| Pineal | 2 (4.3) |
| Temporal lobe | 1 (2.1) |
| Spinal cord | 1 (2.1) |
| Tumor diagnosis | |
| Pilocytic astrocytoma | 10 (21.3) |
| Ependymoma (PFA n = 5) | 6 (12.8) |
| Medulloblastoma | 5 (10.6) |
| Craniopharyngioma | 5 (10.6) |
| Low-grade glioma | 3 (6.4) |
| Diffuse midline glioma | 2 (4.3) |
| Choroid plexus carcinoma | 2 (4.3) |
| AT/RT | 2 (4.3) |
| Ganglioglioma | 2 (4.3) |
| Glioneuronal tumor | 2 (4.3) |
| Pilomyxoid astrocytoma | 2 (4.3) |
| ETMR | 1 (2.1) |
| High-grade glioma | 1 (2.1) |
| Germ cell tumor | 1 (2.1) |
| Neurofibroma | 1 (2.1) |
| Hemangioblastoma | 1 (2.1) |
| Metastatic CNS neuroblastoma | 1 (2.1) |